TARRYTOWN, N.Y., April 29, 2019 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) will webcast management presentations as follows:
- Bank of America Merrill Lynch 2019 Healthcare Conference at 8:00 a.m. Pacific Time (11:00 a.m. Eastern Time) on Wednesday, May 15, 2019
- Barclays 2019 Biopharmaceuticals CEO/CFO Conference Call Series at 11:00 a.m. Eastern Time on Friday, May 17, 2019
- UBS 2019 Global Healthcare Conference at 10:00 a.m. Eastern Time on Monday, May 20, 2019
The sessions may be accessed from the "Investors & Media" page of Regeneron's website at http://investor.regeneron.com/events-and-presentations. Replays of the conference call and webcasts will be archived on the Company's website and will be available for 30 days.
About Regeneron Pharmaceuticals, Inc.
Regeneron (NASDAQ:REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to seven FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases and rare diseases.
Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, such as VelocImmune® which produces optimized fully-human antibodies, and ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world.
For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.
View original content:http://www.prnewswire.com/news-releases/regeneron-announces-upcoming-investor-conference-presentations-300839896.html
SOURCE Regeneron Pharmaceuticals, Inc.